Drug Pricing Watchdog Identifies Most Significant Price Hikes

AbbVie’s anti-inflammatory blockbuster Humira accounted for nearly $1.4 billion in additional unsupported U.S. drug spending last year, the Institute for Clinical and Economic Review says.

Makers of seven of 10 top drugs in the U.S. hiked those drugs’ prices substantially in 2020 with no new evidence of improved safety or effectiveness, led by AbbVie’s anti-inflammatory blockbuster Humira, an influential drug pricing watchdog group says.

The

Read More »

After Successful House Vote, Attention Turns to Senate on Major Drug Pricing Bill

Congressional debate over lowering drug prices has shifted to the U.S. Senate.

Congressional debate over lowering drug prices has shifted to the U.S. Senate following House passage of the $1.75 trillion Build Back Better social spending bill on Friday.

Congress has been on break this week for the Thanksgiving holiday. It returns

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Michael Yount, CEO, Avita

Michael Yount

Q: Where did you grow up?

Conway, Pennsylvania (approximately 20 miles NW of Pittsburgh). I bleed black and gold – yes, I even cheer for the Pirates!

Read More »

News Alert: Novo Nordisk Joins Sanofi in Appealing Court’s 340B Contract Pharmacy Decision

Novo Nordisk yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi appealed earlier in the day.

Drug manufacturer Novo Nordisk late yesterday appealed a federal district judge’s Nov. 5 joint ruling in its and fellow manufacturer Sanofi’s 340B contract pharmacy lawsuits. Sanofi filed its appeal earlier yesterday.

Novo Nordisk’s notice of appeal, like Sanofi’s, is

Read More »

News Alert: Sanofi Is the Second Manufacturer to Appeal a 340B Contract Pharmacy Court Ruling

Drug manufacturer Sanofi is appealing a federal district judge’s Nov. 5 ruling in its 340B contract pharmacy lawsuit.

Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.

Sanofi’s one-sentence Nov. 19 notification to the federal government defendants and U.S. Chief District

Read More »

News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule

HRSA has asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation.

The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.

The proposed rule’s purpose is unknown. HRSA published a

Read More »

Appeals Court Raises Procedural Questions About Lilly’s 340B Contract Pharmacy Case

A federal appeals court is questioning whether a lower court's ruling in Lilly's 340B contract pharmacy suit is "ready for appellate review."

Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.

In an unsigned pair of orders on Tuesday, the federal appeals court in Chicago questioned

Read More »

GOP Congressman Slams PBMs for Taking Away Safety Net Providers’ 340B Savings

Rep. Jake La Turner (R-Kan.) said yesterday he is concerned about PBMs "pickpocketing" health centers and other safety net providers' 340B savings.

A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.

340B health centers and other providers “are reporting that

Read More »

HIV Care Providers Sound Alarm About Threats to 340B Savings

HIV care professionals are raising an alarm about threats to 340B savings and their consequences for patient care.

HIV care professionals are warning the public that threats to 340B drug discount savings “will compromise access to affordable care, treatment, and prevention services for underserved people with and at risk for HIV.”

The American Academy of HIV Medicine, the

Read More »

For the First Time Since Pandemic, Some 340B Providers Are Being Audited in Person

HRSA has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

HRSA told 340B Report in mid-September that in October it would resume

Read More »